尽管深圳市持续推进生育友好型社会建设、优化孕产医疗服务体系，但公立医院内针对孕产妇和新生儿 的商业推销乱象仍屡禁不止，严重干扰就医秩序、影响就医体验。究其根源，这一乱象的形成是多重因 素叠加的结果，核心可归结为以下三方面症结。 深圳市妇幼保健院（福强院区）内张贴的提示。 即便医院联系驻院民警介入，对推销人员也仅以批评教育为主，无法从根本上遏制其逐利动机。也正因 法律依据的缺失，此类推销行为长期游走于监管灰色地带，既加重医院管理负担，也持续困扰患者，进 一步助长了推销人员在医疗场所的肆意渗透。 02 人员管控难题，识别防控收效甚微 推销人员流动性强、伪装手段多样，导致医院的防控与识别工作难度大，是乱象难以根治的重要原因。 这些推销团队多采取 "游击" 战术，人员组成灵活、流动频繁，且专选午间等医护人员相对短缺的时段 集中活动；他们衣着普通，刻意混杂在患者与家属中，甚至通过挂号获取入院资格，让安保人员难以快 速识别。 据深圳市妇幼保健院提供的数据，该院为管控推销行为持续投入大量人力物力，平均每月驱离、劝导的 推销人员约600人次，却依旧屡禁不止、收效有限。即便多家医院强化巡逻、张贴告示，推销者仍能借 助院区通道复 ...

证券日报网讯 2月12日，迪安诊断在互动平台回答投资者提问时表示，X-med临床科研大数据平台是"具 体应用与核心底座"的关系，X-med平台为专病库建设提供了统一的标准化数据中台支撑，确保项目质 量与效率；而专病库项目则是X-med平台能力在具体疾病领域的深度垂直应用与商业落地，二者共同验 证并强化了公司"产品+服务+数字化"的整体解决方案能力 （文章来源：证券日报） ...

消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属 于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常 性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。当期业绩增长主要由金融资产的投资收益和 公允价值变动贡献，而非临床CRO核心业务驱动。 里昂发布研报称，泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能 力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。该行下调泰格医药2027财年盈测 7%，以反映长期投资收益的不确定因素增加。 泰格医药（300347）(03347)尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港元。 ...

消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属 于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常 性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。当期业绩增长主要由金融资产的投资收益和 公允价值变动贡献，而非临床CRO核心业务驱动。 里昂发布研报称，泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能 力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。该行下调泰格医药2027财年盈测 7%，以反映长期投资收益的不确定因素增加。 智通财经APP获悉，泰格医药(03347)尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港 元。 ...

（文章来源：21世纪经济报道） 外国人打飞的来中国看病，是图便宜，还是保命？质子治疗价格仅为新加坡一半，算不算"降维打击"？ 国际患者涌入，会抢走我们的医疗资源吗？一个视频，讲清中国医疗的"实力兑现"！ ...

Group 1 - The core viewpoint of the report indicates that while the order situation for Tigermed (3347.HK) has improved, the market is more focused on the company's order conversion revenue efficiency and investment realization capability [1] - Citic Securities has lowered Tigermed's earnings forecast for the fiscal year 2027 by 7% to reflect increased uncertainty regarding long-term investment returns [1] - The target price for Tigermed's H-shares has been reduced from HKD 68.2 to HKD 59.9, and the target price for its A-shares has been decreased from RMB 81.9 to RMB 72 [1]

Core Insights - The article highlights the business dynamics of Ciming Health Checkup, a member of the Meiyan Health Group, noting that there are no significant stock-related announcements but the operational developments are noteworthy Business Development - In 2025, Ciming Health Checkup Wuhan Co., Ltd. will expand its business scope to include medical beauty services and drug retail, indicating a diversification strategy [2] Business and Technology Advancement - Chengdu Ciming Health Checkup Center is implementing AI-assisted diagnostic systems and has introduced smart devices in 2023 to enhance service efficiency, having served over 1.5 million people cumulatively [3] Operational Status - In 2024, Ciming Health Checkup Wuhan Co., Ltd. reported an insured population of 355 individuals and a cumulative service volume exceeding 3.01 million, reflecting a solid operational foundation [4]

Core Viewpoint - The collaboration between Shandong and Gansu provinces focuses on consolidating poverty alleviation achievements and promoting rural revitalization through industrial cooperation, livelihood support, and regional synergy, with significant progress made in various sectors over the past year [2][9]. Industrial Cooperation - Shandong and Gansu have implemented 526 assistance projects, attracting 170 enterprises to invest in Gansu, leading to the employment and income increase of 65,800 rural laborers from Gansu [2][5]. - In Linxia Prefecture, Shandong invested 140 million yuan to support the development of the cattle and sheep industry cluster, resulting in a total industrial chain output value of 31.1 billion yuan [3]. - The two provinces are developing four major specialty agricultural industry belts, with a planting area of 1.77 million acres, enhancing market access for local products [3][5]. Livelihood Empowerment - The collaboration emphasizes improving living standards, with Shandong sending 70 officials and 744 technical professionals to Gansu, establishing medical and educational support programs [6][8]. - In 2025, the sales of Gansu agricultural products in Shandong are projected to reach 4.323 billion yuan, with 980 million yuan exported to countries like the USA, Japan, and South Korea [8][11]. Regional Synergy - A comprehensive cooperation mechanism has been established, with Shandong and Gansu forming partnerships between 19 counties in Shandong and 24 counties in Gansu, enhancing the effectiveness of collaborative efforts [9][11]. - The two provinces are focusing on four key actions: enhancing specialty industries, building industrial clusters, consumer support, and improving labor cooperation, expanding collaboration into multiple sectors [9][11]. Cultural and Tourism Integration - The collaboration has led to the creation of tourism routes and promotional activities, with Shandong tourists to Gansu expected to exceed 8.2152 million by 2025, marking a 6.93% increase [11][13]. - Efforts are being made to cultivate local talent in Gansu, ensuring sustainable development and self-reliance through technology transfer and management experience sharing [11][13].

Core Insights - The main focus of the news is the significant inflow of capital into specific stocks, indicating strong investor interest and potential market trends. Group 1: Stock Performance and Capital Inflow - The top stock by capital inflow is Yingweike, with an inflow of 1.297 billion yuan and a price increase of 8.68% [1][2] - Leo Group follows with an inflow of 1.123 billion yuan and a price increase of 5.33% [1][2] - TBEA has an inflow of 545 million yuan and a price increase of 3.42% [1][2] - Western Materials shows an inflow of 504 million yuan with a price increase of 5.61% [1][2] - Tianfu Communication has an inflow of 462 million yuan and a notable price increase of 9.79% [1][2] Group 2: Sector Analysis - The stocks listed belong to various sectors, including specialized equipment, internet services, power grid equipment, and communication devices, indicating diverse investment interests [2][3] - The energy metals sector is represented by Shengtun Mining, which has an inflow of 395 million yuan and a price increase of 10.03% [1][2] - The healthcare sector is highlighted by WuXi AppTec, with an inflow of 389 million yuan and a price increase of 3.78% [1][2] Group 3: Additional Notable Stocks - Copper Crown Copper Foil has an inflow of 370 million yuan and a significant price increase of 11.36% [1][2] - Ningde Times, a key player in the battery sector, has an inflow of 334 million yuan with a price increase of 1.82% [1][2] - Other notable stocks include Yunnan Tin with an inflow of 288 million yuan and a price increase of 1.8% [1][3]

Core Viewpoint - Meinian Health (002044) plans to participate in the pre-restructuring of Bangjie Co., Ltd. (002634) to integrate the industry chain, while its AI medical business is experiencing rapid revenue growth, benefiting from industry policy expectations [1][2] Recent Events - On January 29, 2026, Meinian Health announced its intention to participate in the pre-restructuring of Bangjie Co., Ltd., designating its wholly-owned subsidiary, Meinian Dake Health, as the restructuring acquirer, aiming to gain control of Bangjie Co., Ltd. This move is intended to integrate industry chain resources and build a "service-hardware-data" triad model to expand new health management business formats. However, the company noted uncertainties regarding its eligibility to participate and the final outcome as a restructuring investor [2] Business Progress - On January 9, 2026, driven by the launch of OpenAI's "ChatGPTHealth" and other features, investment enthusiasm in AI medical themes has surged. Meinian Health's AI products and the "Health Xiaomei" system have been implemented, with AI technology revenue reaching 250 million yuan in Q3 2025, representing a year-on-year growth of 71.02%. The company continues to optimize operational efficiency through AI [3] Industry Policy Status - Market analysis indicates that in the second half of 2026, healthcare industry policies will be intensively implemented, including the expansion of medical insurance payments, promotion of cancer early screening, and support for the scaling of AI medical services. These developments may provide Meinian Health with opportunities for customer growth and revenue increase [4] Recent Stock Performance - On February 10, 2026, Meinian Health's stock price rose by 2.41%, with a net inflow of main funds amounting to 20.914 million yuan and a trading volume of 784 million yuan. Since the beginning of the year, the stock price has accumulated a rise of 36.74%, indicating high investor interest [5]